These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37627722)

  • 21. Implementation of Chromatic Super CAZ/AVI
    Bianco G; Boattini M; Comini S; Leone A; Bondi A; Zaccaria T; Cavallo R; Costa C
    Eur J Clin Microbiol Infect Dis; 2022 Sep; 41(9):1165-1171. PubMed ID: 35933457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs.
    Fröhlich C; Sørum V; Thomassen AM; Johnsen PJ; Leiros HS; Samuelsen Ø
    mSphere; 2019 Mar; 4(2):. PubMed ID: 30918055
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates.
    Gaibani P; Lewis RE; Volpe SL; Giannella M; Campoli C; Landini MP; Viale P; Re MC; Ambretti S
    Int J Infect Dis; 2017 Dec; 65():1-3. PubMed ID: 28951106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of the in vitro activity of ceftazidime/avibactam against a global collection of multidrug-resistant Klebsiella spp. from the INFORM surveillance programme (2015-2017).
    Rossolini GM; Stone GG
    Int J Antimicrob Agents; 2020 Sep; 56(3):106111. PubMed ID: 32721602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ceftazidime/Avibactam-Based Versus Polymyxin B-Based Therapeutic Regimens for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infection in Critically Ill Patients: A Retrospective Cohort Study.
    Zheng G; Cai J; Zhang L; Chen D; Wang L; Qiu Y; Deng H; Bai H; Bian X; He J
    Infect Dis Ther; 2022 Oct; 11(5):1917-1934. PubMed ID: 35976531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and mortality of ceftazidime/avibactam-based regimens in carbapenem-resistant Gram-negative bacteria infections: A retrospective multicenter observational study.
    Zhuang HH; Chen Y; Hu Q; Long WM; Wu XL; Wang Q; Xu TT; Qu Q; Liu YP; Xiao YW; Qu J
    J Infect Public Health; 2023 Jun; 16(6):938-947. PubMed ID: 37087853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of ceftazidime-avibactam compared to other antimicrobials for the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae strains, a systematic review and meta-analysis.
    Karampatakis T; Tsergouli K; Lowrie K
    Microb Pathog; 2023 Jun; 179():106090. PubMed ID: 37004964
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness analysis of ceftazidime-avibactam as definitive treatment for treatment of carbapenem-resistant
    Kong W; Yang X; Shu Y; Li S; Song B; Yang K
    Front Public Health; 2023; 11():1118307. PubMed ID: 36926178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emergence of Hypervirulent Ceftazidime/Avibactam-Resistant
    Li D; Liao W; Huang HH; Du FL; Wei DD; Mei YF; Long D; Wan LG; Liu Y; Zhang W
    Infect Drug Resist; 2020; 13():2673-2680. PubMed ID: 32821131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of ceftazidime-avibactam in solid organ transplant recipients with bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae.
    Pérez-Nadales E; Fernández-Ruiz M; Natera AM; Gutiérrez-Gutiérrez B; Mularoni A; Russelli G; Pierrotti LC; Pinheiro Freire M; Falcone M; Tiseo G; Tumbarello M; Raffaelli F; Abdala E; Bodro M; Gervasi E; Fariñas MC; Seminari EM; Castón JJ; Marín-Sanz JA; Gálvez-Soto V; Rana MM; Loeches B; Martín-Dávila P; Pascual Á; Rodríguez-Baño J; Aguado JM; Martínez-Martínez L; Torre-Cisneros J;
    Am J Transplant; 2023 Jul; 23(7):1022-1034. PubMed ID: 37028515
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of ceftazidime/avibactam against carbapenem-nonsusceptible Klebsiella penumoniae isolates collected during the first wave of the SARS-CoV-2 pandemic: a Southern Italy, multicenter, surveillance study.
    La Bella G; Lopizzo T; Lupo L; Angarano R; Curci A; Manti B; La Salandra G; Mosca A; De Nittis R; Arena F
    J Glob Antimicrob Resist; 2022 Dec; 31():236-238. PubMed ID: 36208851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suboptimal drug exposure leads to selection of different subpopulations of ceftazidime-avibactam-resistant Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae in a critically ill patient.
    Gaibani P; Gatti M; Rinaldi M; Crovara Pesce C; Lazzarotto T; Giannella M; Lombardo D; Amadesi S; Viale P; Pea F; Ambretti S
    Int J Infect Dis; 2021 Dec; 113():213-217. PubMed ID: 34656787
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ceftazidime-Avibactam for the Treatment of Central Nervous System Infection Caused by Pan Drug-Resistant Carbapenem-Resistant Klebsiella Pneumoniae: A Case Report.
    Zhang Y; Hou G; Zhang L; Li S
    Infect Drug Resist; 2024; 17():3501-3506. PubMed ID: 39157745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutations in porin LamB contribute to ceftazidime-avibactam resistance in KPC-producing Klebsiella
    Guo Y; Liu N; Lin Z; Ba X; Zhuo C; Li F; Wang J; Li Y; Yao L; Liu B; Xiao S; Jiang Y; Zhuo C
    Emerg Microbes Infect; 2021 Dec; 10(1):2042-2051. PubMed ID: 34551677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resistance to Ceftazidime/Avibactam in
    Campogiani L; Vitale P; Lodi A; Imeneo A; Fontana C; D'Agostini C; Compagno M; Coppola L; Spalliera I; Malagnino V; Teti E; Iannetta M; Andreoni M; Sarmati L
    Antibiotics (Basel); 2023 Apr; 12(5):. PubMed ID: 37237722
    [No Abstract]   [Full Text] [Related]  

  • 36. Update of clinical application in ceftazidime-avibactam for multidrug-resistant Gram-negative bacteria infections.
    Zhen S; Wang H; Feng S
    Infection; 2022 Dec; 50(6):1409-1423. PubMed ID: 35781869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In Vitro Activities and Inoculum Effects of Ceftazidime-Avibactam and Aztreonam-Avibactam against Carbapenem-Resistant
    Kim T; Lee SC; Bae M; Sung H; Kim MN; Jung J; Kim MJ; Kim SH; Lee SO; Choi SH; Kim YS; Chong YP
    Antibiotics (Basel); 2020 Dec; 9(12):. PubMed ID: 33334045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Whole-Genome Sequencing and Molecular Analysis of Ceftazidime-Avibactam-Resistant KPC-Producing
    Errico G; Del Grosso M; Pagnotta M; Marra M; Carollo M; Cerquetti M; Fogato E; Cesana E; Gentiloni Silverj F; Zabzuni D; Rossini A; Pantosti A; Tinelli M; Monaco M; Giufrè M
    Antibiotics (Basel); 2023 Aug; 12(8):. PubMed ID: 37627702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antimicrobial Activity of Ceftazidime-Avibactam and Comparators Against Fluoroquinolone-Resistant
    Kiratisin P; Arhin FF; Stone G; Utt E
    Microb Drug Resist; 2022 Nov; 28(11):1019-1027. PubMed ID: 36251881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ceftazidime-avibactam activity against Gram-negative respiratory isolates collected between 2018 and 2019.
    Kempf M; Arhin FF; Stone G; Utt E
    J Glob Antimicrob Resist; 2022 Dec; 31():239-247. PubMed ID: 36208850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.